HiXCap™: Rational 5′ Cap Design Enabling Clinical Advancement of Next-Generation mRNA Therapeutics

We present a whitepaper on optimizing mRNA 5′ cap structures with HiXCap™ to overcome immune-mediated translational inhibition and accelerate the clinical development of next-generation mRNA therapeutics.

Key Insights:

• Industry Challenges: Conventional mRNA cap analogs (GAG Cap1, GAAG Cap2) are vulnerable to IFIT1 binding under inflammatory conditions, which suppresses protein translation, limits therapeutic efficacy, and hinders the clinical application of mRNA vaccines and mRNA drugs.
• Proposed Solution: Develop rationally engineered HiXCap™ cap analogs with N1 2'-O-ethyl modifications to create steric hindrance against IFIT1, while maintaining excellent compatibility with standard in vitro transcription (IVT) and LNP delivery workflows for mRNA production.
• Key Benefits:
  • Strong resistance to IFIT1 binding, sustaining high protein expression under immune stress and inflammatory environments
  • Superior translation efficiency applicable to both uridine and m1Ψ modified mRNA across diverse therapeutic scenarios
  • Proven efficacy in cancer immunotherapy and infectious disease vaccines, supporting faster immune response and tumor inhibition
• Choosing Cap Analogs for mRNA Therapeutics: Key criteria include IFIT1 evasion capability, translation performance, IVT compatibility, purity and low endotoxin, as well as validated in vivo efficacy and clinical readiness.
• Hongene's Role: Leveraging structural biology and synthetic technology, Hongene develops three core HiXCap™ series (E1/E2/E3) with high purity and stable batch consistency. HiXCap™ E2 has entered clinical trials for multiple cancer treatments, providing reliable cap solutions for biotechs and pharmaceutical companies developing mRNA therapeutics.

(To explore the full structural design principles, in vitro/in vivo experimental data, clinical progress and case studies, download the complete whitepaper.)